Literature DB >> 32632232

Benefit of dapagliflozin is independent of LVEF.

Gregory B Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32632232     DOI： 10.1038/s41569-020-0419-3

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.

Authors:  Pooja Dewan; Scott D Solomon; Pardeep S Jhund; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; David L DeMets; Marc S Sabatine; Olof Bengtsson; Mikaela Sjöstrand; Anna Maria Langkilde; Inder S Anand; Jan Bělohlávek; Vijay K Chopra; Andrej Dukát; Masafumi Kitakaze; Béla Merkely; Eileen O'Meara; Morten Schou; Pham Nguyen Vinh; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2020-06-15       Impact factor: 15.534
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.